About Us
R&D
Pipeline
News
Partnering
Careers
Contact
中
中

Achieve precision medicine with disruptive strategies

We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science

Achieve precision medicine with disruptive strategies

We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science

Mission drives innovation, and innovation improves quality of life

We bring solutions to cancer drug resistance from our deeply integrated strength in chemistry, biology and medicine.
About Us

The next generation of cancer therapies that meet urgent clinical needs

We are building a pipeline of targeted cancer therapies by harnessing our artificial intelligence platform and expertise of structure-based design.
Our Pipeline

AACR 2025 | TargetRx Revealed First Preclinical Data on Two Novel, Oral Potent Protein Degraders

TGRX-3544 (highly mutant-selective KIT degrader) and TGRX-3911 (potent BTK degrader) were selected for poster presentation at AACR 2025.
News

Collaboration and Creation

Looking forward to working with you to explore innovative technologies and conduct research and development of products.
Collaboration

Fighting cancer is our mission, make it yours

Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us

Fighting cancer is our mission, make it yours

Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us

About Us

R&D

Pipeline

News

Partnering

Careers

Contact

  • Tel: +86-0755-86934300
  • 3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
  • E-mail: targetrx@tjrbiosciences.com

Follow Us

Copyright © 2021 Shenzhen TargetRx, Inc.
粤ICP备2021119553号